Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3.
Early breast cancer
FRMD3
Hsa-miR-3651
Local control
Prediction
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
06
05
2021
accepted:
25
10
2021
pubmed:
6
12
2021
medline:
3
3
2022
entrez:
5
12
2021
Statut:
ppublish
Résumé
MicroRNAs are small non-coding RNAs with pivotal regulatory functions in multiple cellular processes. Their significance as molecular predictors for breast cancer was demonstrated in the past 15 years. The aim of this study was to elucidate the role of hsa-miR-3651 for predicting of local control (LC) in early breast cancer. By means of high-throughput technology, hsa-miR-3651 was found to be differentially expressed between patients who experienced local relapse compared to those without (N = 23; p = 0.0035). This result could be validated in an independent cohort of 87 patients using RT-qPCR (p < 0.0005). In a second analysis step with a chip-based microarray containing 70,523 probes of potential target molecules, FERM domain protein 3 (FRMD3) was found to be the most down-regulated protein (N = 21; p = 0.0016). Computational analysis employing different prediction algorithms revealed FRMD3 as a likely downstream target of hsa-miR-3651 with an 8mer binding site between the two molecules. This could be validated in an independent patient set (N = 20, p = 0.134). The current study revealed that hsa-miR-3651 is a predictor of LC in early breast cancer via its putative target protein FRMD3. Since microRNAs interfere in multiple pathways, the results of this hypothesis generating study may contribute to the development of tailored therapies for breast cancer in the future.
Sections du résumé
BACKGROUND
BACKGROUND
MicroRNAs are small non-coding RNAs with pivotal regulatory functions in multiple cellular processes. Their significance as molecular predictors for breast cancer was demonstrated in the past 15 years. The aim of this study was to elucidate the role of hsa-miR-3651 for predicting of local control (LC) in early breast cancer.
RESULTS
RESULTS
By means of high-throughput technology, hsa-miR-3651 was found to be differentially expressed between patients who experienced local relapse compared to those without (N = 23; p = 0.0035). This result could be validated in an independent cohort of 87 patients using RT-qPCR (p < 0.0005). In a second analysis step with a chip-based microarray containing 70,523 probes of potential target molecules, FERM domain protein 3 (FRMD3) was found to be the most down-regulated protein (N = 21; p = 0.0016). Computational analysis employing different prediction algorithms revealed FRMD3 as a likely downstream target of hsa-miR-3651 with an 8mer binding site between the two molecules. This could be validated in an independent patient set (N = 20, p = 0.134).
CONCLUSION
CONCLUSIONS
The current study revealed that hsa-miR-3651 is a predictor of LC in early breast cancer via its putative target protein FRMD3. Since microRNAs interfere in multiple pathways, the results of this hypothesis generating study may contribute to the development of tailored therapies for breast cancer in the future.
Identifiants
pubmed: 34865205
doi: 10.1007/s12282-021-01308-y
pii: 10.1007/s12282-021-01308-y
pmc: PMC8885475
doi:
Substances chimiques
FRMD3 protein, human
0
MIRN3651 microRNA, human
0
MicroRNAs
0
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
274-286Subventions
Organisme : Paracelsus Medizinische Privatuniversität
ID : PMU-FFF E-12/16/085-SED
Informations de copyright
© 2021. The Author(s).
Références
Nucleic Acids Res. 2003 Feb 15;31(4):e15
pubmed: 12582260
Genes (Basel). 2020 Nov 26;11(12):
pubmed: 33255991
PLoS One. 2012;7(6):e39011
pubmed: 22723919
Dev Biol. 2006 Jun 15;294(2):280-91
pubmed: 16650401
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
Dis Colon Rectum. 2014 Jan;57(1):23-31
pubmed: 24316942
Diabetes. 2010 Aug;59(8):2075-9
pubmed: 20460425
Diabetol Metab Syndr. 2015 Dec 30;7:118
pubmed: 26719775
J Hum Genet. 2003;48(2):101-6
pubmed: 12601556
Diabetes. 2009 Jun;58(6):1403-10
pubmed: 19252134
PLoS Genet. 2017 May 12;13(5):e1006728
pubmed: 28498854
Cancer Biomark. 2019;24(1):19-30
pubmed: 30594916
Biol Rev Camb Philos Soc. 2018 Nov;93(4):1955-1986
pubmed: 29797774
Cancer Res. 2005 Aug 15;65(16):7065-70
pubmed: 16103053
Biotechniques. 2019 Dec;67(6):276-285
pubmed: 31621384
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Oncogene. 2007 Jun 28;26(30):4464-8
pubmed: 17260017
PLoS One. 2014 Feb 13;9(2):e88273
pubmed: 24551085
J Cell Sci. 2008 Apr 15;121(Pt 8):1159-64
pubmed: 18349074
Cancer. 2002 Nov 15;95(10):2059-67
pubmed: 12412158
Breast. 2017 Dec;36:89-95
pubmed: 28988610
Int J Mol Med. 2020 Mar;45(3):956-966
pubmed: 31922246
Lancet Oncol. 2008 Apr;9(4):331-41
pubmed: 18356109
J Ovarian Res. 2020 Aug 27;13(1):99
pubmed: 32854743
Bioinformatics. 2010 Oct 1;26(19):2363-7
pubmed: 20688976
PLoS One. 2012;7(5):e36170
pubmed: 22623953
Oncol Rep. 2014 Mar;31(3):1429-36
pubmed: 24452363
Onco Targets Ther. 2019 Aug 29;12:7045-7054
pubmed: 31695418
PLoS One. 2014 Mar 14;9(3):e91884
pubmed: 24632820
Nat Commun. 2018 Dec 7;9(1):5228
pubmed: 30531873
Clin Epigenetics. 2016 Mar 08;8:28
pubmed: 26962366
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Front Genet. 2021 Jul 12;12:657658
pubmed: 34322151
Int J Clin Oncol. 2021 Sep;26(9):1689-1697
pubmed: 34043102
Biochem Biophys Res Commun. 2015 Sep 11;465(1):30-4
pubmed: 26210449
BMC Bioinformatics. 2011 May 07;12:137
pubmed: 21548974
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809